AspirinUseforthePrimaryPreventionofCardiovascularDisease
andColorectalCancer:U.S.PreventiveServicesTaskForce
RecommendationStatement
Kirsten Bibbins-Domingo, PhD, MD, MAS, on behalf of the U.S. Preventive Services Task Force*
Description:Update of the 2009 USPSTF recommendation on
aspirin use to prevent cardiovascular disease (CVD) events and
the 2007 recommendation on aspirin and nonsteroidal anti-
inflammatory drug use to prevent colorectal cancer (CRC).
Methods:The USPSTF reviewed 5 additional studies of aspirin
for the primary prevention of CVD and several additional analy-
ses of CRC follow-up data. The USPSTF also relied on commis-
sioned systematic reviews of all-cause mortality and total cancer
incidence and mortality and a comprehensive review of harms.
The USPSTF then used a microsimulation model to systemati-
cally estimate the balance of benefits and harms.
Population:This recommendation applies to adults aged 40
years or older without known CVD and without increased bleed-
ing risk.
Recommendation:The USPSTF recommends initiating low-
dose aspirin use for the primary prevention of CVD and CRC in
adults aged 50 to 59 years who have a 10% or greater 10-year
CVD risk, are not at increased risk for bleeding, have a life ex-
pectancy of at least 10 years, and are willing to take low-dose
aspirin daily for at least 10 years. (B recommendation)
The decision to initiate low-dose aspirin use for the primary
prevention of CVD and CRC in adults aged 60 to 69 years who
have a 10% or greater 10-year CVD risk should be an individual
one. Persons who are not at increased risk for bleeding, have a
life expectancy of at least 10 years, and are willing to take low-
dose aspirin daily for at least 10 years are more likely to benefit.
Persons who place a higher value on the potential benefits than
the potential harms may choose to initiate low-dose aspirin. (C
recommendation)
The current evidence is insufficient to assess the balance of
benefits and harms of initiating aspirin u
2016+USPSTF建议声明：阿司匹林用于心血管疾病和结直肠癌的一级预防.pdf